Skip to main content
EyePoint Pharmaceuticals, Inc. logo

EyePoint Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · EYPT ISIN · US74440J1016 LEI · 549300QE1RU34T50MR69 US Manufacturing
Open in API
Filings indexed 1,019 across all filing types
Latest filing 2019-01-29 Director's Dealing
Country US United States of America
Listing US EYPT

About EyePoint Pharmaceuticals, Inc.

https://eyepointpharma.com/

EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for serious retinal diseases. The company leverages its proprietary Durasert E™ technology, a bio-erodible platform for sustained intraocular drug delivery, to create durable therapies. Its lead investigational product, DURAVYU™ (EYP-1901), combines the tyrosine kinase inhibitor vorolanib with the Durasert E™ system for the potential treatment of VEGF-mediated retinal diseases. The company's goal is to improve patient outcomes and reduce treatment burden by providing long-lasting treatments for chronic eye conditions.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2019-01-29 English
PRIMARY DOCUMENT
Director's Dealing
2019-01-29 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated January 25, 2019, reporting the appointment of a new director, Dr. David R. Guyer, to the Board of Directors of EyePoint Pharmaceuticals, Inc. It details the increase in board size, the appointment, compensation, and related agreements. The key section is Item 5.02, which specifically covers "Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers." This matches the definition of Board/Management Information (MANG), which includes announcements of changes in the company's board of directors or senior management. The document is not a full annual report, audit report, or earnings release, nor is it a proxy or voting result announcement. It is a regulatory filing form used to announce management changes. Therefore, the correct classification is MANG with high confidence.
2019-01-29 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to an at-the-market offering of common stock by EyePoint Pharmaceuticals, Inc. It details the terms of the offering, use of proceeds, risk factors, and other information relevant to a capital raising transaction. The presence of terms like "At Market Issuance Sales Agreement," "shares of common stock," and references to Nasdaq listing and sales agent compensation confirm this is a capital/financing update document. It is not an annual report, earnings release, or any other type of report but specifically a financing-related filing. Therefore, the correct classification is Capital/Financing Update (CAP). The document length and detail support a high confidence level.
2019-01-18 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement for an at-the-market equity program to sell shares, including details about the sales agreement and related legal opinions. There are no financial statements or comprehensive financial data presented, nor is this an annual or quarterly report. The document is primarily an announcement of a financing agreement and related legal exhibits. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 5189 characters, which is sufficient to contain substantive information about the financing event rather than just a brief announcement. Hence, the classification is CAP with high confidence.
2019-01-18 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text indicates it includes a press release about commercial updates and product launch expectations, but does not contain financial statements or detailed financial data. The document length is 2817 characters, which is relatively short and consistent with a regulatory announcement rather than a full report. There is no indication of detailed financial results, audit information, or management discussion. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2019-01-14 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.